“As people live longer, improving quality of life is paramount,” said Alex Morgan, partner at Khosla Ventures, which funded Rubedo’s first round of venture capital funding. . “Rubedo targets senescent cells, which are responsible for age-related diseases. This first effort brings us one step closer to achieving a healthier lifespan.”
Senescent cells age and permanently stop dividing, but they do not die. Over time, they accumulate in tissues and release high levels of inflammatory chemicals and immunomodulators that contribute to aging.
Rubedo will first begin a Phase 1 study to evaluate the efficacy of RLS-1469 in the treatment of incurable inflammatory skin diseases, chronic atopic dermatitis, and chronic psoriasis. Preclinical data shows that the drug significantly reduces senescent cells in the skin that cause these chronic degenerative conditions, and there is hope that RLS-1469 will provide long-term relief for patients with chronic degenerative conditions. It has been.
“Our mission is to invest in innovative companies that serve vast markets and change the world for the better,” said another contributor, Founder and General Manager of Aalen Innovation Capital. – Partner Alice Newcomb Ellis said. “Rubedo’s innovative approach to targeting senescent cells is an exciting step toward developing chronic age-related treatments and advances biotechnology from treatment to prevention or disease reversal. We believe.”
Professor Rubedo is also developing other treatments that selectively target senescent cells in lung diseases to meet unmet medical needs. The team is extremely grateful for the financial and other support it has received from its sponsors.
“The significant experience and capital that our investors bring to Rubedo will help us rapidly advance our programs,” said Ali Siam, Chief Business Officer of Rubedo Life Sciences. Ta. “We look forward to working with these leaders. Their extensive experience in clinical development will be invaluable as Rubedo enters its next phase of growth.”
Rubedo’s proprietary AI-enhanced drug discovery platform, Alembic, identifies specific druggable targets for the development of disease-modifying therapies.
Source: Business Wire
